Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares

January 21, 2026 by InsiderTrades.com

Key Points

Marshall Urist sold 20,000 shares of Royalty Pharma on Jan. 16 at an average price of $39.52 (≈$790,400), leaving him with 40,000 shares — part of a string of insider sales since December that reduced his position by one-third.
Royalty Pharma raised its quarterly dividend to $0.235 (annualized $0.94), giving a 2.4% yield; the record date and ex-dividend date are Feb. 20 and the dividend is payable Mar. 10.
The stock trades with a market cap of about $22.6 billion, a P/E of ~29.6 and a 52-week range of $29.66–$41.70, while analysts carry a consensus “Moderate Buy” and a $45.60 price target.

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction on Friday, January 16th. The stock was sold at an average price of $39.52, for a total transaction of $790,400.00. Following the transaction, the executive vice president owned 40,000 shares in the company, valued at approximately $1,580,800. This trade represents a 33.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks

Marshall Urist also recently made the following trade(s):

On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $40.78, for a total value of $815,600.00.
On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.32, for a total value of $786,400.00.
On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total value of $767,600.00.
On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total value of $766,400.00.
On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $913,526.10.
On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $714,174.30.
On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total value of $931,686.69.
On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Stock Down 1.2%

Shares of NASDAQ RPRX opened at $39.09 on Wednesday. The company's 50 day moving average price is $39.31 and its 200-day moving average price is $37.48. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. Royalty Pharma PLC has a 52-week low of $29.66 and a 52-week high of $41.70. The company has a market capitalization of $22.56 billion, a P/E ratio of 29.61, a price-to-earnings-growth ratio of 1.51 and a beta of 0.43.

1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The company had revenue of $609.29 million during the quarter, compared to analysts' expectations of $765.01 million. Equities analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be given a $0.235 dividend. This is a boost from Royalty Pharma's previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Friday, February 20th. This represents a $0.94 annualized dividend and a dividend yield of 2.4%. Royalty Pharma's dividend payout ratio is 66.67%.

Hedge Funds Weigh In On Royalty Pharma

4 Healthcare Stocks With Massive Gains—and More to Come

A number of large investors have recently modified their holdings of the company. Smartleaf Asset Management LLC increased its stake in Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 790 shares in the last quarter. USA Financial Formulas acquired a new position in shares of Royalty Pharma during the second quarter valued at about $32,000. Financial Consulate Inc. bought a new stake in shares of Royalty Pharma during the third quarter worth about $35,000. Larson Financial Group LLC increased its position in shares of Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 306 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Royalty Pharma by 113.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,428 shares of the biopharmaceutical company's stock worth $51,000 after acquiring an additional 760 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Wall Street Zen upgraded Royalty Pharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday. TD Cowen boosted their price target on Royalty Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday, December 11th. Morgan Stanley cut their price target on Royalty Pharma from $55.00 to $54.00 and set an "overweight" rating on the stock in a report on Friday, October 10th. Leerink Partners set a $45.00 price objective on shares of Royalty Pharma in a research note on Thursday, December 11th. Finally, Weiss Ratings downgraded shares of Royalty Pharma from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Saturday, October 25th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $45.60.

Check Out Our Latest Stock Report on RPRX

About Royalty Pharma

(Get Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.